Physician profile
Van S Breeding
NPI 1801841572
$975.59
in general payments reported to CMS, 2019-2025
17 companies · $27.68 in 2025
The $27.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $31.30 · 2021: $12.77 · 2022: $26.45 · 2023: $161 · 2024: $157 · 2025: $27.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.07 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $247.09 | 2019-2023 | |
| Lilly USA, LLC | $151.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $107.39 | 2024 | Dupixent |
| Abbvie INC. | $80.75 | 2019-2023 | Dalvance |
| Braeburn INC. | $73.76 | 2023-2024 | Brixadi |
| Grifols USA, LLC | $51.86 | 2019-2023 | Prolastin-C Liquid |
| Novo Nordisk INC | $45.47 | 2019 | |
| Amgen INC. | $35.00 | 2019 | |
| Insulet Corporation | $34.25 | 2021-2023 | Omnipod |
| Amarin Pharma, INC. | $31.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.49 | 2019 | |
| Glaxosmithkline, LLC. | $17.25 | 2024 | Arexvy, Trelegy Ellipta |
| Alkermes, INC. | $17.06 | 2019 | |
| Pfizer INC. | $15.27 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2024 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.94 | 2025 | Rexulti |
| Gilead Sciences, INC. | $13.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Breeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.